We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

73 hedge funds and large institutions have $45.3M invested in Outlook Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

39% more capital invested

Capital invested by funds: $32.6M → $45.3M (+$12.7M)

4% more funds holding

Funds holding: 70 → 73 (+3)

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

0.03% more ownership

Funds ownership: 0.53% → 0.57% (+0.03%)

Holders
73
Holders Change
+3
Holders Change %
+4.29%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
23
Reduced
21
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Vista Finance
Missouri
+$1.54M
2
BlackRock
BlackRock
New York
+$1.19M
3
N
Nuveen
North Carolina
+$1.11M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$516K
5
Northern Trust
Northern Trust
Illinois
+$256K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$834K
2
Renaissance Technologies
Renaissance Technologies
New York
-$679K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$546K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$517K
5
IA
IndexIQ Advisors
New York
-$255K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$32K -$140K -4,480 -83%
Victory Capital Management
52
Victory Capital Management
Texas
$28K +$94 +3 +0.3%
EWM
53
Endurance Wealth Management
Rhode Island
$27K – – –
AB
54
Amalgamated Bank
New York
$26K -$1.91K -61 -8%
AF
55
Amalgamated Financial
New York
$26K +$22.6K +725 New
MCA
56
MSH Capital Advisors
Arizona
$23.1K +$20.3K +650 New
Legal & General Group
57
Legal & General Group
United Kingdom
$22K +$4.87K +156 +34%
MFGP
58
Marshall Financial Group (Pennsylvania)
Pennsylvania
$21K – – –
RIA
59
Realta Investment Advisors
Delaware
$20K – – –
CB
60
CNB Bank
Pennsylvania
$18K – – –
TCA
61
Transcend Capital Advisors
New Jersey
$18K – – –
CAPTRUST Financial Advisors
62
CAPTRUST Financial Advisors
North Carolina
$18K +$15.6K +500 New
CCM
63
Crew Capital Management
Ohio
$18K +$15.6K +500 New
FMI
64
F/M Investments
District of Columbia
$18K +$15.6K +500 New
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$16.8K -$15.1K -482 -51%
Royal Bank of Canada
66
Royal Bank of Canada
Ontario, Canada
$12K -$21.1K -677 -66%
AIP
67
Ameritas Investment Partners
Nebraska
$12K – – –
APA
68
American Portfolios Advisors
New York
$7.12K – – –
Citigroup
69
Citigroup
New York
$7K -$29.4K -942 -82%
UBS Group
70
UBS Group
Switzerland
$5K -$45.5K -1,457 -91%
PWMG
71
Prestige Wealth Management Group
New Jersey
$2K – – –
Fidelity Investments
72
Fidelity Investments
Massachusetts
$2K +$1.69K +54 +1,350%
IA
73
IndexIQ Advisors
New York
– -$255K -9,385 Closed
Jacobs Levy Equity Management
74
Jacobs Levy Equity Management
New Jersey
– -$159K -5,850 Closed
SFI
75
Susquehanna Fundamental Investments
Pennsylvania
– -$42K -1,532 Closed
1 2
3
4

OTLK Hedge Fund Activity: Q1 2022 in Review

73 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2022, worth a combined $45.3M — up 39% from $32.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OTLK positions and 9 closed out — a net gain of 5 holders — while 23 added to existing stakes and 21 trimmed.

The largest buyer was Vista Finance, opening a new position worth an estimated $1.54M. The largest seller was Two Sigma Investments, cutting an estimated $834K.

  • 73 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2022, up from 70 in Q4 2021.
  • Funds reported $45.3M of Outlook Therapeutics stock for Q1 2022, up 39% quarter-over-quarter.
  • 14 funds opened new Outlook Therapeutics positions in Q1 2022 and 9 closed out, a net change of +5 holders.
  • The largest Outlook Therapeutics buyer in Q1 2022 was Vista Finance, an estimated $1.54M added.
  • The largest Outlook Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $834K sold.

Based on aggregated 13F filings for Q1 2022.